Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MMRV (AMP)
MMRV · 1 trial · 4 indications
Sera were tested for VZV Immunoglobulin (IgG) antibody levels by a glycoprotein enzyme-linked immunosorbent assay (gpELISA)
Sera were tested for measles virus IgG antibody levels by an ELISA
Sera were tested for mumps virus IgG antibody levels by an enzyme-linked immunosorbent assay (ELISA)
Sera were tested for rubella virus IgG antibody levels by an ELISA
Sera were tested for VZV IgG antibody levels by gpELISA
Sera were tested for measles virus IgG antibody levels by ELISA
Sera were tested for mumps virus IgG antibody levels by ELISA
Sera were tested for rubella virus IgG antibody levels by ELISA
| Arm | Type | Description |
|---|---|---|
| MMRV (AMP) | EXPERIMENTAL | Participants received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP) |
| MMRV (2006 process) | ACTIVE_COMPARATOR | Participants received two 0.5 mL subcutaneous injections of MMRV vaccine made with the 2006 manufacturing process |
| Name | Type | Description |
|---|---|---|
| MMRV (AMP) | BIOLOGICAL | Measles, mumps, rubella, and VZV vaccine made with an alternative manufacturing process. Participants will receive two 0.5 mL subcutaneous injections. |
| MMRV (2006 process) | BIOLOGICAL | Measles, mumps, rubella, and VZV vaccine made with the 2006 manufacturing process. Participants will receive two 0.5 mL subcutaneous injections. |
Inclusion Criteria: * Negative clinical history for measles, mumps, rubella, varicella, and zoster Exclusion Criteria: * Received any measles, mumps, rubella, or varicella vaccine, either alone or in any combination at any time prior to the study, or is anticipated to receive any of these vaccine...
MMRV is an investigational combination vaccine developed by Merck & Company, Inc. (ticker MRK) that targets measles, mumps, rubella, and varicella in a single product. It is made using an alternative manufacturing process, abbreviated AMP, and is being studied in children from 12 months of age.
MMRV is being developed to protect against measles together with mumps, rubella, and varicella in one combination vaccine. The Phase 3 trial enrolled healthy children starting at 12 months of age and evaluated safety, tolerability, and immunogenicity against all four diseases, including measles.
Merck & Company, Inc., which trades under the ticker MRK, is the developer of MMRV. The vaccine is produced using an alternative manufacturing process, which is why the program is also referred to as MMRV (AMP). Merck sponsored the Phase 3 study of the candidate.
MMRV is in Phase 3 development. The program's single registered trial, NCT01536405, is a completed Phase 3 study, and no trials are currently listed as active. MMRV is an investigational vaccine candidate and has not been established as approved for use.
MMRV has been studied in one clinical trial, NCT01536405, titled Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP). It was a completed Phase 3 randomized, double-blind, active-controlled study that enrolled 1,412 healthy volunteers.
Yes. MMRV (AMP) is another name for MMRV, with AMP standing for alternative manufacturing process. Both names refer to the same Merck & Company, Inc. (ticker MRK) Phase 3 combination vaccine candidate against measles, mumps, rubella, and varicella.